Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03330132
PHASE4

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong

Sponsor: The University of Hong Kong

View on ClinicalTrials.gov

Summary

This study allows to evaluate the strength and duration of immune responses between annual receipt of standard inactivated vaccine and alternative potent vaccines, including annual receipt of adjuvanted inactivated vaccine, annual receipt of high-dose inactivated vaccine, annual receipt of recombinant HA vaccine, and the alternate combinations of the former three vaccines over four years, for identifying improved vaccination strategies for influenza vaccination in older adults in a location experiencing a subtropical pattern in influenza activity.

Official title: Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial

Key Details

Gender

All

Age Range

65 Years - 82 Years

Study Type

INTERVENTIONAL

Enrollment

1861

Start Date

2017-10-07

Completion Date

2026-12

Last Updated

2023-12-11

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Standard inactivated influenza vaccine (NH formulation)

0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.

BIOLOGICAL

MF 59 adjuvanted inactivated influenza vaccine (NH formulation)

0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.

BIOLOGICAL

High-dose inactivated influenza vaccine (NH formulation)

0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

BIOLOGICAL

Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)

0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.

Locations (1)

The University of Hong Kong

Hong Kong, China